Novelion Therapeutics (NVLN) was quite active in trading today. The stock has been mostly bullish since Thursday morning after the company confirmed that it had secured funding to continue its operations into 2019. The company has products already approved by the FDA and has six other products in development either at phase 2 or phase 3 status. However, NVLN has a relatively high amount of debt and thus news of its securing funding set the stock into motion. Here’s a recap of what’s happened to NVLN over the last two days.
Novelion Therapeutics Finds A Backer
Read Similar Articles
The Week Ahead: SAY IT ISN’T SO
This is the one week the entire Prosper roster is in the same room. Three days at The Wynn Las Vegas Resort – nine coaches, headline guests, live trading, and a floor full of traders leveling up together. SAY IT ISN’T SO It was quite the week for markets. In fact, some investors may have been […]
Read ArticleScott Bauer: Can the Market Survive Another AI Scare?
The Nasdaq just logged four straight losing weeks, and a strong jobs report pushed Fed hike odds higher. Scott Bauer joined the IBKR Podcast to break down what drove the selloff, what the market is pricing in for December, and why he thinks volatility is too cheap right now.
Read ArticleThe Week Ahead: CORRECTION
This is the one week the entire Prosper roster is in the same room. Three days at The Wynn Las Vegas Resort – nine coaches, headline guests, live trading, and a floor full of traders leveling up together. WE STAND CORRECTED It was a brutal week for tech investors, and a volatile one for broader indexes, […]
Read ArticleRead Similar Articles
The Fed, Oil, and What Earnings Season Really Means
Scott Bauer joined the IBKR Podcast this week to break down what moved markets last week and what investors need to watch heading into the next stretch of earnings season. From lagging inflation data to big tech CapEx concerns, Scott did not hold back.
Read ArticleThe Week Ahead: Happy 250
The Dow rose more than 1% to a record closing high on Thursday ahead of the long holiday weekend as a softer-than-expected U.S. jobs report eased worries about interest rate hikes, while another sharp drop in chipmaker stocks weighed on the Nasdaq. The second half of 2026 kicked off this week much the same as […]
Read ArticleThe Week Ahead: Darn Inflation
A renewed sell-off in technology stocks grabbed headlines this week. The Nasdaq index fell 4.5%, closing lower 5 days in a row, led by a large 5.5% decline in the so-called Magnificent 7 mega cap names. Meanwhile, the post IPO exuberance around SpaceX appears to be fading, with shares now down 25% from their peak. […]
Read Article


